Larvol Delta - Ankyra-Therapeutics-Receives-FDA-IND-and-Health-Canada-CTA-Approval-to-Advance-FirstInClass-Selective-Anchored-Immunotherapy-Agent-ANK101-into-Human-Trials-in-Solid-Tumors

ANK-101 - Ankyra Therap

https://www.businesswire.com/news/home/20231024848390/en/Ankyra-Therapeutics-Receives-FDA-IND-and-Health-Canada-CTA-Approval-to-Advance-First-In-Class-Selective-Anchored-Immunotherapy-Agent-ANK-101-into-Human-Trials-in-Solid-Tumors

Oct 24, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next